Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells

Alinejad, Vahideh; Somi, Mohammad Hossein; Baradaran, Behzad; Akbarzadeh, Parvin; Atyabi, Fatemeh; Kazerooni, Hanif; Kafil, Hossein Samadi; Maleki, Leili Aghebati; Mansouri, Homayoon Siah; Yousefi, Mehdi

doi:10.1016/j.biopha.2016.06.037

Cited by 73 publications

(25 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data suggesting the promoting or inhibiting role of Th-17 and IL-17 on tumorigenesis have been reported. Some findings (Alinejad et al 2017) have suggested that through activation of the ERK1/ERK2, NF-kb and BCL-2 pathways, the IL-17B/IL-17RB system promotes inflammation, breast cancer progression as well as resistance to chemotherapy drugs (Alinejad et al 2016). Conversely, some findings have shown that IL-17 significantly induce MDSC differentiation, inhibit their proliferation and trigger apoptosis through the JAK/STAT3 pathway in vitro (Ma et al 2018), whereas other findings (Benchetrit et al 2002, Kryczek et al 2009 have supported an anti-tumour effect against certain tumours.…”

Section: Sex Hormones and The Immune Responsementioning

confidence: 99%

Tumour growth and immune evasion as targets for a new strategy in advanced cancer

Nicolini¹,

Rossi²,

Carpi³

2018

Endocrine-Related Cancer

View full text Add to dashboard Cite

It has become clearer that advanced cancer, especially advanced breast cancer, is an entirely displayed pathological system that is much more complex than previously considered. However, the direct relationship between tumour growth and immune evasion can represent a general rule governing the pathological cancer system from the initial cancer cells to when the system is entirely displayed. Accordingly, a refined pathobiological model and a novel therapeutic strategy are proposed. The novel therapeutic strategy is based on therapeutically induced conditions (undetectable tumour burden and/or a prolonged tumour 'resting state'), which enable an efficacious immune response in advanced breast and other types of solid cancers.

show abstract

Section: Sex Hormones and The Immune Responsementioning

confidence: 99%

Tumour growth and immune evasion as targets for a new strategy in advanced cancer

Nicolini¹,

Rossi²,

Carpi³

2018

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…Overall, cell viability is frequently above 70% when evaluated by MTS assay or its derivatives (MTT, XTT, etc.). [57][58][59][60][61] For instance, Raw 264.7 cells treated with a mannosylated CH-graftpolyethylenimine copolymer showed ~95% viability after a 24 h exposure at concentrations around our TPC. 57 In PBMC, CH gold nanoparticles showed low cytotoxicity for concentrations up to 75 μM.…”

Section: Discussionmentioning

confidence: 89%

<p>Evidence Supporting the Safety of Pegylated Diethylaminoethyl-Chitosan Polymer as a Nanovector for Gene Therapy Applications</p>

Rondon¹,

Benabdoun²,

Vallières³

et al. 2020

IJN

View full text Add to dashboard Cite

Purpose: Diethylaminoethyl-chitosan (DEAE-CH) is a derivative with excellent potential as a delivery vector for gene therapy applications. The aim of this study is to evaluate its toxicological profile for potential future clinical applications. Methods: An endotoxin-free chitosan (CH) modified with DEAE, folic acid (FA) and polyethylene glycol (PEG) was used to complex small interfering RNA (siRNA) and form nanoparticles (DEAE 12-CH-PEG-FA 2 /siRNA). Based on the guidelines from the International Organization for Standardization (ISO), the American Society for Testing and Materials (ASTM), and the Nanotechnology Characterization Laboratory (NCL), we evaluated the effects of the interaction between these nanoparticles and blood components. In vitro screening assays such as hemolysis, hemagglutination, complement activation, platelet aggregation, coagulation times, cytokine production, and reactive species, such as nitric oxide (NO) and reactive oxygen species (ROS), were performed on erythrocytes, plasma, platelets, peripheral blood mononuclear cells (PBMC) and Raw 264.7 macrophages. Moreover, MTS and LDH assays on Raw 264.7 macrophages, PBMC and MG-63 cells were performed. Results: Our results show that a targeted theoretical plasma concentration (TPC) of DEAE 12-CH-PEG-FA 2 /siRNA nanoparticles falls within the guidelines' thresholds: <1% hemolysis, 2.9% platelet aggregation, no complement activation, and no effect on coagulation times. ROS and NO production levels were comparable to controls. Cytokine secretion (TNF-α, IL-6, IL-4, and IL-10) was not affected by nanoparticles except for IL-1β and IL-8. Nanoparticles showed a slight agglutination. Cell viability was >70% for TPC in all cell types, although LDH levels were statistically significant in Raw 264.7 macrophages and PBMC after 24 and 48 h of incubation. Conclusion: These DEAE 12-CH-PEG-FA 2 /siRNA nanoparticles fulfill the existing ISO, ASTM and NCL guidelines' threshold criteria, and their low toxicity and blood biocompatibility warrant further investigation for potential clinical applications.

show abstract

“…In formulations of controlled DDSs, synthetic polymers attract more attention than biopolymers due to the considerable potential for the design of their structure and modifications of their physicochemical properties ( Figure 2) [8]. Synthetic polymeric micelles exhibita high capacityto incorporate a broad range of bioactive molecules, such as antisense oligonucleotides [21], plasmid DNA [22], proteins [23], small interfering ribonucleic acids (siRNAs) [24], messenger RNAs (mRNAs) [25] and photosensitizers [26], by tailoring the core-forming segments of the block copolymers. In fact, several poly-ion complex (PIC) micelles have been designed that incorporate negatively charged biomolecules by electrostatic interaction with positively charged block copolymers [21,27].…”

Section: Polymeric Nanoparticles (Nps)mentioning

confidence: 99%

“…By introducing hydrophobic molecules such as cholesterol to the core [30], PIC micelles become more stable, with a longer half-life in the bloodstream, allowing for the delivery of intact biomolecules to therapeutic targets. PIC micelles obtained from block copolymers with a core-forming polycation such as polyaspartamides, support enhanced delivery of biomacromolecules to the cytosol of cells, and the gene transfection in vitro and in vivo [25,[29][30][31][32][33][34][35]. In recent years, the great potential of synthetic polymers as drug carriers has been highlighted, particularly because of the possibility to develop DDSs with a target sustained/controlled release of drugs [1].…”

Section: Polymeric Nanoparticles (Nps)mentioning

confidence: 99%

Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

Conventional chemotherapy is the most common therapeutic method for treating cancer by the application of small toxic molecules thatinteract with DNA and causecell death. Unfortunately, these chemotherapeutic agents are non-selective and can damage both cancer and healthy tissues, producing diverse side effects, andthey can have a short circulation half-life and limited targeting. Many synthetic polymers have found application as nanocarriers of intelligent drug delivery systems (DDSs). Their unique physicochemical properties allow them to carry drugs with high efficiency, specificallytarget cancer tissue and control drug release. In recent years, considerable efforts have been made to design smart nanoplatforms, including amphiphilic block copolymers, polymer-drug conjugates and in particular pH- and redox-stimuli-responsive nanoparticles (NPs). This review is focused on a new generation of polymer-based DDSs with specific chemical functionalities that improve their hydrophilicity, drug loading and cellular interactions.Recentlydesigned multifunctional DDSs used in cancer therapy are highlighted in this review.

show abstract

Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells

Cited by 73 publications

References 36 publications

Tumour growth and immune evasion as targets for a new strategy in advanced cancer

Tumour growth and immune evasion as targets for a new strategy in advanced cancer

<p>Evidence Supporting the Safety of Pegylated Diethylaminoethyl-Chitosan Polymer as a Nanovector for Gene Therapy Applications</p>

Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy

Contact Info

Product

Resources

About